Literature DB >> 2450707

Defective intralesional interferon-gamma activity in patients with lepromatous leprosy.

B Volc-Platzer1, H Stemberger, T Luger, T Radaszkiewicz, G Wiedermann.   

Abstract

Cryostat sections of full-thickness skin biopsies from 21 patients along the whole spectrum of leprosy were subjected to immunohistological examination with special regard to defective lymphokine production. There was an inverse relationship between intra-lesional IL-1 reactivity and IL-2R expression, in that the latter was markedly observed in tuberculoid lesions. Whenever epithelioid cell containing granulomas were present in paucibacillary forms, significant reactivity within the central phagocytic cells with the monoclonal antibody directed against interferon-gamma was detectable. The keratinocytes covering tuberculoid lesions abundantly expressed class II alloantigens (HLA-DR antigens), indicating high intra-lesional interferon-gamma activity. In contrast, multibacillary forms revealed significant anti-IL-1 reactivity within the cellular infiltrate. IL-2R bearing cells were virtually absent as was anti-HLA-DR reactivity of the keratinocytes, underlining a defective intra-lesional interferon-gamma activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2450707      PMCID: PMC1541447     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes.

Authors:  F M Brodsky
Journal:  Immunogenetics       Date:  1984       Impact factor: 2.846

2.  Anti-Leu-3/T4 antibodies react with cells of monocyte/macrophage and Langerhans lineage.

Authors:  G S Wood; N L Warner; R A Warnke
Journal:  J Immunol       Date:  1983-07       Impact factor: 5.422

3.  Reactivity of Langerhans cells with hybridoma antibody.

Authors:  E Fithian; P Kung; G Goldstein; M Rubenfeld; C Fenoglio; R Edelson
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

4.  Initial characterization of monoclonal antibodies against human monocytes.

Authors:  V Ugolini; G Nunez; R G Smith; P Stastny; J D Capra
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

5.  Monoclonal antibodies to human myelomonocyte differentiation antigens in the diagnosis of acute myeloid leukemia.

Authors:  W Knapp; O Majdic; H Stockinger; P Bettelheim; K Liszka; U Köller; C Peschel
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

6.  Classification of leprosy according to immunity. A five-group system.

Authors:  D S Ridley; W H Jopling
Journal:  Int J Lepr Other Mycobact Dis       Date:  1966 Jul-Sep

7.  Lymphocyte suppression in leprosy induced by unique M. leprae glycolipid.

Authors:  V Mehra; P J Brennan; E Rada; J Convit; B R Bloom
Journal:  Nature       Date:  1984 Mar 8-14       Impact factor: 49.962

8.  Induction of delayed-type hypersensitivity to Mycobacterium leprae in healthy individuals.

Authors:  A H Smelt; R J Rees; F Y Liew
Journal:  Clin Exp Immunol       Date:  1981-06       Impact factor: 4.330

9.  Genetically restricted suppressor T-cell clones derived from lepromatous leprosy lesions.

Authors:  R L Modlin; H Kato; V Mehra; E E Nelson; X D Fan; T H Rea; P K Pattengale; B R Bloom
Journal:  Nature       Date:  1986 Jul 31-Aug 6       Impact factor: 49.962

10.  Defective gamma interferon production in leprosy. Reversal with antigen and interleukin 2.

Authors:  N Nogueira; G Kaplan; E Levy; E N Sarno; P Kushner; A Granelli-Piperno; L Vieira; V Colomer Gould; W Levis; R Steinman
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

View more
  9 in total

Review 1.  T cell and cytokine patterns in leprosy skin lesions.

Authors:  P A Sieling; R L Modlin
Journal:  Springer Semin Immunopathol       Date:  1992

2.  Detection of transforming growth factor-beta 1 in dermal lesions of different clinical forms of leprosy.

Authors:  I M Goulart; F Figueiredo; T Coimbra; N T Foss
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

3.  Human T cell responses to peptides of the Mycobacterium leprae 45-kD serine-rich antigen.

Authors:  S Brahmbhatt; R Hussain; S Zafar; G Dawood; T H M Ottenhoff; J W Drijfhout; G Bothamley; S Smith; F V Lopez; H M Dockrell
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

4.  Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions.

Authors:  Anna K Andersson; MeherVani Chaduvula; Sara E Atkinson; Saroj Khanolkar-Young; Suman Jain; Lavanya Suneetha; Sujai Suneetha; Diana N J Lockwood
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

5.  Immunocytochemical localization of inducible nitric oxide synthase and transforming growth factor-beta (TGF-beta) in leprosy lesions.

Authors:  S Khanolkar-Young; D Snowdon; D N Lockwood
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

6.  Immunohistologic assessment of cytokine production of infiltrating cells in various forms of leprosy.

Authors:  J Arnoldi; J Gerdes; H D Flad
Journal:  Am J Pathol       Date:  1990-10       Impact factor: 4.307

7.  Expression of CC and CXC chemokines and chemokine receptors in human leprosy skin lesions.

Authors:  A A Kirkaldy; A C Musonda; S Khanolkhar-Young; S Suneetha; D N J Lockwood
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

8.  Serum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions.

Authors:  A Iyer; M Hatta; R Usman; S Luiten; L Oskam; W Faber; A Geluk; P Das
Journal:  Clin Exp Immunol       Date:  2007-11       Impact factor: 4.330

9.  The Effects of Prednisolone Treatment on Cytokine Expression in Patients with Erythema Nodosum Leprosum Reactions.

Authors:  Edessa Negera; Stephen L Walker; Kidist Bobosha; Yonas Bekele; Birtukan Endale; Azeb Tarekegn; Markos Abebe; Abraham Aseffa; Hazel M Dockrell; Diana N Lockwood
Journal:  Front Immunol       Date:  2018-02-09       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.